Ocuphire Pharma Inc. (OCUP): Price and Financial Metrics
OCUP Price/Volume Stats
| Current price | $2.99 | 52-week high | $6.60 |
| Prev. close | $3.05 | 52-week low | $2.48 |
| Day low | $2.90 | Volume | 285,100 |
| Day high | $3.09 | Avg. volume | 239,267 |
| 50-day MA | $3.12 | Dividend yield | N/A |
| 200-day MA | $3.97 | Market Cap | 67.69M |
OCUP Stock Price Chart Interactive Chart >
OCUP POWR Grades
- Value is the dimension where OCUP ranks best; there it ranks ahead of 99.69% of US stocks.
- OCUP's strongest trending metric is Quality; it's been moving up over the last 177 days.
- OCUP ranks lowest in Stability; there it ranks in the 3rd percentile.
OCUP Stock Summary
- With a price/earnings ratio of 3.19, OCUPHIRE PHARMA INC P/E ratio is greater than that of about merely 2.8% of stocks in our set with positive earnings.
- For OCUP, its debt to operating expenses ratio is greater than that reported by merely 0.22% of US equities we're observing.
- Revenue growth over the past 12 months for OCUPHIRE PHARMA INC comes in at 9,158.28%, a number that bests 99.85% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to OCUPHIRE PHARMA INC are PSTV, ARQT, MIRO, VXRT, and TGTX.
- Visit OCUP's SEC page to see the company's official filings. To visit the company's web site, go to www.rexahn.com.
OCUP Valuation Summary
- OCUP's price/sales ratio is 1.3; this is 63.89% lower than that of the median Healthcare stock.
- OCUP's price/earnings ratio has moved up 29.4 over the prior 219 months.
Below are key valuation metrics over time for OCUP.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OCUP | 2023-11-03 | 1.3 | 1.5 | 3.1 | 0.9 |
| OCUP | 2023-11-02 | 1.3 | 1.5 | 3.1 | 0.9 |
| OCUP | 2023-11-01 | 1.3 | 1.6 | 3.2 | 1.1 |
| OCUP | 2023-10-31 | 1.3 | 1.6 | 3.2 | 1.0 |
| OCUP | 2023-10-30 | 1.3 | 1.6 | 3.2 | 1.0 |
| OCUP | 2023-10-27 | 1.3 | 1.5 | 3.1 | 0.9 |
Ocuphire Pharma Inc. (OCUP) Company Bio
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. (from company website @ https://www.ocuphire.com/about)
Latest OCUP News From Around the Web
Below are the latest news stories about OCUPHIRE PHARMA INC that investors may wish to consider to help them evaluate OCUP as an investment opportunity.
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate UpdateSuccessful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2 Phase 3 Presbyopia Trial Met Primary Endpoint; Viatris Expected to Continue Phase 3 Development in 1H 2024 George Magrath, M.D., M.B.A., M.S. Named as CEO; Conference Call Scheduled for December 5th, 2023, at 10 AM ET FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasd |
Declining Stock and Solid Fundamentals: Is The Market Wrong About Ocuphire Pharma, Inc. (NASDAQ:OCUP)?With its stock down 32% over the past three months, it is easy to disregard Ocuphire Pharma (NASDAQ:OCUP). However... |
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic RetinopathyAgreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score Company Plans to Submit a Special Protocol Assessment (SPA) APX3330 has the Potential to be the First Oral Option for 8M Non-Proliferative Diabetic Retinopathy (NPDR) Patients in the US FARMINGTON HILLS, Mich., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing s |
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to George Magrath, M.D., M.B.A., M.S., the Company’s newly appoin |
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and DirectorDr. Magrath Brings Proven Executive Leadership, Medical and Clinical Expertise in Ophthalmic Drug DevelopmentFARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and member of th |
OCUP Price Returns
| 1-mo | 9.12% |
| 3-mo | N/A |
| 6-mo | -21.93% |
| 1-year | -8.28% |
| 3-year | -53.93% |
| 5-year | N/A |
| YTD | -15.30% |
| 2022 | -5.36% |
| 2021 | -42.53% |
| 2020 | -15.05% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...